HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bernardete Pessoa Selected Research

Fluocinolone Acetonide (Capex)

1/2022Changes in Ganglion Cell Layer Thickness after Treatment with the 0.2 µg/day Fluocinolone Acetonide Implant in Vitrectomized and Nonvitrectomized Eyes with Diabetic Macular Edema.
1/2021Fluocinolone Acetonide 0.19 mg Implant in Patients with Cystoid Macular Edema Due To Irvine-Gass Syndrome.
1/2021Optical Coherence Tomography Biomarkers: Vitreous Status Influence in Outcomes for Diabetic Macular Edema Therapy with 0.19-mg Fluocinolone Acetonide Implant.
1/2020Challenging Clinical Cases - A Walk Through Supplemental Therapy with Intravitreal Ranibizumab Therapy Following Treatment of Diabetic Macular Edema with the 0.19 mg Fluocinolone Acetonide Implant (ILUVIEN®).
1/2020Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN®) and Follow-Up Considerations/Recommendations.
1/2019Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes.
1/2019Long-term management of non-ischemic central retinal vein occlusion with fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN®).
1/2018Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Bernardete Pessoa Research Topics

Disease

15Macular Edema
08/2022 - 01/2018
2Epiretinal Membrane (Epiretinal Membranes)
08/2022 - 07/2021
2Diabetic Retinopathy (Retinopathy, Diabetic)
08/2022 - 01/2020
2Edema (Dropsy)
11/2021 - 01/2020
2Retinal Perforations
02/2021 - 01/2016
1Ganglion Cysts (Ganglion)
01/2022
1Cataract (Cataracts)
07/2021
1Vascular Diseases (Vascular Disease)
03/2021
1Transthyretin-Related Hereditary Amyloidosis
03/2021
1Amyloidosis
03/2021
1Myopia
02/2021
1Atrophy
02/2021
1Vision Disorders (Hemeralopia)
01/2021
1Retinal Vein Occlusion
01/2019

Drug/Important Bio-Agent (IBA)

8Fluocinolone Acetonide (Capex)FDA LinkGeneric
01/2022 - 01/2018
4Ranibizumab (Lucentis)FDA Link
11/2021 - 01/2020
4Retinaldehyde (Retinal)IBA
11/2021 - 02/2021
3Biomarkers (Surrogate Marker)IBA
08/2022 - 01/2021
3Dexamethasone (Maxidex)FDA LinkGeneric
01/2021 - 01/2019
2Adrenal Cortex Hormones (Corticosteroids)IBA
01/2021 - 01/2020
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2019 - 01/2019
1Triamcinolone (Aristocort)FDA Link
01/2021
1Bevacizumab (Avastin)FDA Link
01/2021
1afliberceptIBA
01/2021
1Vascular Endothelial Growth FactorsIBA
01/2020
1microplasminIBA
01/2016

Therapy/Procedure

4Vitrectomy
08/2022 - 01/2019
3Injections
11/2021 - 01/2019
3Therapeutics
01/2021 - 01/2020
2Aftercare (After-Treatment)
01/2022 - 01/2021
2Intravitreal Injections
01/2021 - 01/2020
1Cataract Extraction
01/2021
1Traction
01/2016